Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Verastem (VSTM) EBITDA: 2018-2025

Historic EBITDA for Verastem (VSTM) over the last 8 years, with Sep 2025 value amounting to -$95.8 million.

  • Verastem's EBITDA fell 299.60% to -$95.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.4 million, marking a year-over-year decrease of 167.70%. This contributed to the annual value of -$130.7 million for FY2024, which is 49.56% down from last year.
  • Verastem's EBITDA amounted to -$95.8 million in Q3 2025, which was down 289.56% from -$24.6 million recorded in Q2 2025.
  • In the past 5 years, Verastem's EBITDA ranged from a high of -$8.3 million in Q2 2024 and a low of -$95.8 million during Q3 2025.
  • Over the past 3 years, Verastem's median EBITDA value was -$24.4 million (recorded in 2023), while the average stood at -$35.6 million.
  • As far as peak fluctuations go, Verastem's EBITDA soared by 66.02% in 2024, and later slumped by 299.60% in 2025.
  • Quarterly analysis of 5 years shows Verastem's EBITDA stood at -$16.5 million in 2021, then fell by 1.79% to -$16.8 million in 2022, then declined by 10.87% to -$20.0 million in 2023, then decreased by 20.10% to -$64.6 million in 2024, then slumped by 299.60% to -$95.8 million in 2025.
  • Its last three reported values are -$95.8 million in Q3 2025, -$24.6 million for Q2 2025, and -$45.5 million during Q1 2025.